1,000
Participants
Start Date
February 17, 2017
Primary Completion Date
October 10, 2017
Study Completion Date
October 10, 2017
Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate
0.5 milliliter (mL), Intramuscular
Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine
0.5 mL, Intramuscular
Investigational Site, Hermitage
Investigational Site, Erie
Investigational Site, Midlothian
Investigational Site, Birmingham
Investigational Site, Dothan
Investigational Site, Goodlettsville
Investigational Site, Tullahoma
Investigational Site, Bardstown
Investigational Site, Nicholasville
Investigational Site, Cleveland
Investigational Site, Fairfield
Investigational Site, Cincinnati
Investigational Site, Dayton
Investigational Site, Council Bluffs
Investigational Site, Bridgeton
Investigational Site, Kansas City
Investigational Site, Omaha
Investigational Site, Metairie
Investigational Site, Jonesboro
Investigational Site, Layton
Investigational Site, Orem
Investigational Site, Roy
Investigational Site, Syracuse
Investigational Site, South Jordan
Investigational Site, Salt Lake City
Investigational Site, Salt Lake City
Investigational Site, Tucson
Investigational Site, Downey
Investigational Site, Paramount
Investigational Site, San Diego
Investigational Site, Gresham
Investigational Site, Anaheim
Investigational Site, Grants Pass
Investigational Site, West Jordan
Investigational Site, Woburn
Investigational Site, San Juan
Sanofi Pasteur, a Sanofi Company
INDUSTRY